Literature DB >> 22159017

Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.

Jeremy D Keenan1, Craig W See, Jeanne Moncada, Berhan Ayele, Teshome Gebre, Nicole E Stoller, Charles E McCulloch, Travis C Porco, Bruce D Gaynor, Paul M Emerson, Julius Schachter, Thomas M Lietman.   

Abstract

PURPOSE: Although trachoma control programs frequently use the World Health Organization (WHO) simplified grading system for trachoma to monitor the clinical response after repeated mass azithromycin treatments, the programmatic relevance of this evaluation after multiple rounds of antibiotic treatments is unclear.
METHODS: Three rounds of annual mass azithromycin were distributed to 12 villages in Ethiopia. Twelve months after the third treatment, children were assessed for follicular trachomatous inflammation (TF) and intense trachomatous inflammation (TI) using the WHO simplified grading system and for ocular chlamydial infection using DNA-based and RNA-based tests. Test characteristics for predicting chlamydial infection were computed assuming a chlamydial RNA-based gold standard. As a secondary analysis, test characteristics were also assessed using a latent class analysis.
RESULTS: The prevalence of RNA evidence of ocular chlamydia was 7.1% (95% confidence interval [CI], 2.7-17.4). A DNA-based test and TF had sensitivities of 61.0% (95% CI, 47.1-73.3) and 65.9% (95% CI, 41.6-83.9), specificities of 100% (95% CI, 99.3-100) and 67.5% (95% CI, 61.0-73.5), and positive predictive values of 100% (95% CI, 86.3-100) and 13.4% (95% CI, 5.5-29.3) compared with an RNA-based gold standard. The latent class analysis confirmed that the RNA-based test was a reasonable choice for a gold standard, with a sensitivity of 100% (95% CI, 67.1-100) and specificity of 99.6% (95% CI, 98.1-100).
CONCLUSIONS: Basing treatment decisions after mass azithromycin distributions on the WHO simplified grading system will maximize the treatment of infected persons compared with a DNA-based test but will also result in more uninfected persons being treated. The RNA-based test was considerably more sensitive, and almost equivalently specific, compared with a DNA-based test. (ClinicalTrials.gov number, NCT00322972.).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22159017      PMCID: PMC3292361          DOI: 10.1167/iovs.11-8493

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  40 in total

Review 1.  Diagnostic test analyses in search of their gold standard: latent class analyses with random effects.

Authors:  E Goetghebeur; J Liinev; M Boelaert; P Van der Stuyft
Journal:  Stat Methods Med Res       Date:  2000-06       Impact factor: 3.021

2.  Detection of Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised.

Authors:  Julius Schachter; Joan M Chow; Holly Howard; Gail Bolan; Jeanne Moncada
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

3.  Comparison of the Gen-Probe APTIMA Combo 2 assay to the AMPLICOR CT/NG assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine samples from Australian men and women.

Authors:  Peter Lowe; Peter O'Loughlin; Kathryn Evans; Michael White; Paul B Bartley; Renu Vohra
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

4.  Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas?

Authors:  Mariko Bird; Chandler R Dawson; Julius S Schachter; Yinghui Miao; Ahmed Shama; Ahmed Osman; Ahmad Bassem; Thomas M Lietman
Journal:  J Infect Dis       Date:  2003-04-30       Impact factor: 5.226

5.  Performance of three nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of self-collected vaginal swabs obtained via an Internet-based screening program.

Authors:  Billie Jo Masek; Nick Arora; Nicole Quinn; Bulbul Aumakhan; Jeff Holden; Andrew Hardick; Patricia Agreda; Mathilda Barnes; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

6.  Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial.

Authors:  Jenafir I House; Berhan Ayele; Travis C Porco; Zhaoxia Zhou; Kevin C Hong; Teshome Gebre; Kathryn J Ray; Jeremy D Keenan; Nicole E Stoller; John P Whitcher; Bruce D Gaynor; Paul M Emerson; Thomas M Lietman
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

7.  Abilities of APTIMA, AMPLICOR, and ProbeTec assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in PreservCyt ThinPrep Liquid-based Pap samples.

Authors:  M Chernesky; D Jang; E Portillo; S Chong; M Smieja; K Luinstra; A Petrich; C Macritchie; R Ewert; B Hayhoe; A Sarabia; F Thompson
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

8.  Location of the origin of replication for the 7.5-kb Chlamydia trachomatis plasmid.

Authors:  J E Tam; C H Davis; R J Thresher; P B Wyrick
Journal:  Plasmid       Date:  1992-05       Impact factor: 3.466

9.  Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.

Authors:  Emily S West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Robin Bailey; Allen Foster; David Mabey; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-01       Impact factor: 4.799

10.  Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.

Authors:  Sheila K West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Allen Foster; Robin L Bailey; David C W Mabey
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

View more
  7 in total

1.  The association between latrine use and trachoma: a secondary cohort analysis from a randomized clinical trial.

Authors:  Meron Haile; Zerihun Tadesse; Sintayehu Gebreselassie; Berhan Ayele; Teshome Gebre; Sun N Yu; Nicole E Stoller; Bruce D Gaynor; Travis C Porco; Paul M Emerson; Thomas M Lietman; Jeremy D Keenan
Journal:  Am J Trop Med Hyg       Date:  2013-09-03       Impact factor: 2.345

2.  Using a nonparametric multilevel latent Markov model to evaluate diagnostics for trachoma.

Authors:  Artemis Koukounari; Irini Moustaki; Nicholas C Grassly; Isobel M Blake; María-Gloria Basáñez; Manoj Gambhir; David C W Mabey; Robin L Bailey; Matthew J Burton; Anthony W Solomon; Christl A Donnelly
Journal:  Am J Epidemiol       Date:  2013-04-01       Impact factor: 4.897

3.  Antibiotics for trachoma.

Authors:  Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch
Journal:  Cochrane Database Syst Rev       Date:  2019-09-26

4.  Short-term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection.

Authors:  Fengchen Liu; Travis C Porco; Abdou Amza; Boubacar Kadri; Baido Nassirou; Sheila K West; Robin L Bailey; Jeremy D Keenan; Thomas M Lietman
Journal:  Parasit Vectors       Date:  2015-10-22       Impact factor: 3.876

Review 5.  The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment.

Authors:  Athumani M Ramadhani; Tamsyn Derrick; David Macleod; Martin J Holland; Matthew J Burton
Journal:  PLoS Negl Trop Dis       Date:  2016-10-26

6.  Development and evaluation of a next-generation digital PCR diagnostic assay for ocular Chlamydia trachomatis infections.

Authors:  Chrissy H Roberts; Anna Last; Sandra Molina-Gonzalez; Eunice Cassama; Robert Butcher; Meno Nabicassa; Elizabeth McCarthy; Sarah E Burr; David C Mabey; Robin L Bailey; Martin J Holland
Journal:  J Clin Microbiol       Date:  2013-05-01       Impact factor: 5.948

Review 7.  Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.

Authors:  Diane K Lavett; Van C Lansingh; Marissa J Carter; Kristen A Eckert; Juan C Silva
Journal:  ScientificWorldJournal       Date:  2013-05-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.